ArticleProstate international2025
Transurethral water vapor therapy (Rezūm) for acute urinary retention with obstructive uropathy: a prospective cohort study with one-year follow-up.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The double-decker technique for transurethral water vapor therapy (Rezūm) in catheter-dependent patients: A step-by-step guide and results from a prospective registry.Investigative and clinical urology · 2026Article
- Comparison of prostatic urethral lift (PUL) versus water vapour thermal therapy (WVTT): A focus on drug-free status and unplanned admissions.BJUI compass · 2026Article
- Asia-Pacific collaborative consensus statements on water vapor thermal therapy (Rezūm) incorporating a systematic review, a two-round Delphi survey, and a consensus meeting.Prostate international · 2026Article
- The "swipe" technique for prostatic urethral lift: a comparative analysis of 200 patients in a prospective cohort.Prostate international · 2026Article
- State-of-the-art in minimally invasive treatments for benign prostatic obstruction.Investigative and clinical urology · 2026Review
- Thulium fiber laser enucleation of the prostate with SOLTIVE™ SuperPulsed laser systems: a prospective evaluation of early outcomes in an Asian cohort.Frontiers in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This prospective cohort study evaluates the safety and efficacy of transurethral water vapor therapy (Rezūm) in men with acute urinary retention (AUR) complicated by obstructive uropathy (acute renal impairment). Patients and methods: Obstructive uropathy was defined per 2012 Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury (AKI) criteria. Rezūm was performed as an ambulatory procedure under local anesthesia. The primary outcome was the proportion of catheter-free patients at 3 and 12 months with stable renal function (i.e. serum creatinine not exceeding +0.3 mg/dL or 1.5 times baseline). Results: Twenty-three consecutive patients were recruited (August 2023-February 2024). Median age was 71 years (interquartile range [IQR]: 67-80) and mean ± standard deviation of prostate size was 57.9 ± 13.8 mL. At 3- and 12-month follow-up, 96% (22/23) were catheter-free with stable renal function. Median time to successful trial without catheter (TWOC) was 36.5 days (IQR: 27.5-42.8 days). Prostate size decreased by 36.8% (P < 0.001) at 3 months. Thirty-day readmissions occurred in 13% (3/23), all Clavien-Dindo grade 1-2. Conclusion: Rezūm shows promise as a safe and effective procedure in AUR with obstructive uropathy, providing durable catheter independence in high-risk patients. It expands minimally invasive surgical therapies (MISTs) indications, particularly as an ambulatory option under local anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.